LACunar Intervention Trial-3 (LACI-3): Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke. Research What is Laci-3? Trial Information Information for Researchers News About us. Patients Who can participate? Sites Which UK hospitals are participating? For Investigators Trial Staff Login Contact the Laci-3 trial team: laci-3@ed.ac.ukLACI-3 is managed by the the Trial Coordinating Centre:LACI-3 TrialCentre for Clinical Brain ScienceChancellor’s Building49 Little France CrescentEdinburghEH16 4SB This article was published on 2024-08-27